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We select the letters for these pages from the rapid 
responses posted on bmj.com favouring those received 
within five days of publication of the article to which they 
refer. Letters are thus an early selection of rapid responses 
on a particular topic. Readers should consult the website 
for the full list of responses and any authors’ replies, which 
usually arrive after our selection.
We compare the self reported sexual activity 
and satisfaction in Swedish 70 year olds1with 
recent data from the Australian longitudinal 
study of health and relationships (ALSHR)—a 
nationally representative random sample of 
men and women aged 16 to 64 who completed 
a computer assisted telephone interview.2 The 
sample had 635 sexagenarians (60-64), most 
(80%) with a regular partner, almost all of them 
married and living with their partner. A quarter 
of women and 15% of men were not in a regular 
relationship. Regular sexual activity was the norm 
for those with a regular partner, both women 
and men reporting an average of three sexual 
experiences a month (table).
Among the attitudinal statements presented to 
respondents was: “An active sex life is important 
for one’s sense of wellbeing”; 78% of women 
91% of men agreed with this statement. On a 
four point scale (not at all, slightly, moderately, 
and very), respondents in relationships were 
asked to indicate the degree of physical pleasure 
in sex with the partner, satisfaction with the 
sexual relationship, and emotional satisfaction 
with the relationship. Although women were 
less likely than men to say that sex was “very” 
pleasurable (56% v 81%), satisfaction with the 
sexual relationship differed less (65% women 
and 72% men reported being very satisfied). 
Men (86%) were more likely than women (72%) 
to say that they found the relationship “very” 
emotionally satisfying.
These data and those of Beckman et al 
are a timely reminder for health providers 
that older people are still sexually active and 
enjoying sexual activity. Given the importance 
of pleasurable sexual activity for these older 
people, it is important that clinicians consider 
sexuality as an important aspect of all patients’ 
wellbeing regardless of their age.
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seroprotection and meningitis c
Meningococcal C booster not 
recommended by evidence
Snape et al recommend that a booster dose of 
meningococcal group C glycoconjugate vaccine 
(MenC) be administered to children entering 
adolescence in the UK in the next five years.1 
However, their study did not look for, or provide, 
any evidence of increasing nasopharyngeal 
carriage in pre-adolescents, and underestimates 
the protective effect of herd immunity on 
those vaccinated in early childhood between 
2000 and 2005 who may have lower levels of 
seroprotection.
MenC vaccination reduces the prevalence 
of nasopharyngeal carriage of serogroup C 
meningococci,2 as well as disease incidence in 
the unvaccinated population.3 Post-licensure 
surveillance of meningococcal group C disease 
in England has not found evidence of reduced 
effectiveness of the vaccine with time, apart 
from in infants, who are now given a booster 
dose at one year.4 In 2007-8 (July to June), only 
28 laboratory confirmed cases were identified 
in England and Wales, compared with over 900 
cases in the year preceding the introduction of 
vaccination.
Mathematical modelling predicts that 
high rates of indirect protection against 
meningococcal group C disease are likely to 
persist, even if the vaccine only provides three 
years’ protection against carriage.5 The most 
recent surveillance data are consistent with 
model predictions of a continued decline in 
disease incidence (figure available on request) 
and suggest that protection against carriage lasts 
somewhere between three and 10 years, with 
the impact on herd immunity likely to persist for 
much longer.
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Funding cancer treatments
ethics of PCt decision making 
on funding cancer treatments
We recently co-chaired the Cancer Agenda 
2008 meeting with leading cancer clinicians. 
One theme that emerged was the high level of 
concern about the ethics of primary care trusts’ 
decision making on funding cancer treatments.
Increasingly, clinicians feel tension between 
their obligations to individual patients and 
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anticipate that further therapeutic targeting of 
the androgen receptor signalling axis in CRPC can 
achieve disease control in a sizeable proportion 
of CRPC patients whose prostate cancer has 
progressed through all currently available 
hormonal treatments.
Nevertheless, although these treatments 
should not be heralded as a cure for metastatic 
CRPC, our research is leading us closer to an 
increased understanding of the biology of this 
disease, which, in turn, increases the likelihood 
of our achieving better long term control of it. 
Abiraterone now needs to be further evaluated 
in the adjuvant setting in high risk patients to 
determine whether it can reduce the risk of 
recurrence.
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competing interests
any affiliation can lead to bias
Lenzer and Brownlee rightly draw attention to the 
problem of undeclared commercial interests that 
conflict with the public interest and influence 
media reporting of medical advances, but there 
is a danger that their diagnosis and proposed 
solution ignore the underlying causes.1
Any affiliation, not just a link to a commercial 
enterprise, can lead to bias, and almost 
everybody has some sort of affiliation, so few 
people are truly independent. However, the 
absence or presence of such affiliations does 
not prove or disprove bias. The actual, rather 
than potential, independence of a commentator 
depends on qualities that are difficult to measure 
such as personal integrity and expertise, 
rather than proxies such as declarations of “no 
commercial interest.”
More importantly, while efforts to identify 
conflicts of interest are important, there is an 
unhealthy trend towards the demonisation 
of everybody who is associated with the 
commercial sector. Commercial interests are 
not always corrupting, and much high quality, 
honest work is carried on outside universities 
and other supposedly independent research 
institutions.
But a very major contributor to the current 
problem is the time pressure under which 
journalists have to operate. It is always 
dangerous for any journalist to rely on just one 
commentator for opinion, even if they do appear 
on an “approved list of independent experts,” 
but it can often be difficult to get experts on the 
phone to express an interesting and coherent 
opinion. Ideally, journalists should be able to 
gain a range of expert views, allowing them to 
identify and detect any outlying opinions that 
seem to have been influenced by bias, lack of 
expertise, etc. It would be far better to encourage 
more experts to make themselves available for 
comment, than to come up with lists of approved 
sources.
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society.1 2 They are trained to provide best care 
for patients but recognise that this conflicts 
with the NHS’s ability to provide optimal care 
to all patients with all conditions in a just 
and equitable way in an economically limited 
system. Societal responsibility for these 
decisions is expressed through the National 
Institute for Health and Clinical Excellence 
(NICE), the Scottish Medicines Consortium, and 
similar bodies.
NICE’s judgments allow for non-approved 
treatments in “exceptional cases.” The 
principle of natural justice supports equity of 
treatment for all. This is being undermined by 
different interpretations of exceptionality; the 
decision to argue for exceptionality can put the 
responsibility—but neither the decision making 
nor the funding—back in the clinician’s court. We 
urge that national guidance be provided to define 
“exceptional cases.”
Professional bodies, and the BMJ, should 
challenge primary care trusts to show they have 
adopted a coherent, cogent, and transparent 
approach to making decisions about funding 
treatments.
timothy s Maughan professor of cancer studies 
Joanne Rule  patient advocacy adviser 
Velindre Hospital, Cardiff Cf14 2tL 
tim.Maughan@velindre-tr.wales.nhs.uk
Competing interests: Cancer Agenda is supported by an 
unconditional education grant from Pfizer oncology. to 
the best of our knowledge, Pfizer Pharmaceuticals, which 
provided this grant, will not benefit financially in any way 
from the publication of our letter summarising the concerns 
which arose at the 2008 meeting.
Godlee F. The world is watching the English experiment. 1 
BMJ 2008;337:a953.(23 July.)
Beach MC, Meredith LS, Halpern J, Ford D. Physician 2 
conceptions of responsibility to individual patients 
and distributive justice in health care. Ann Fam Med 
2005;3:53-9.
Cite this as: BMJ 2008;337:a1243
new prostate cancer drug
Prostate cancer’s day in the sun
Recently we and others have studied different 
anti-cancer drugs in patients with castration 
resistant prostate cancer (CRPC).1 2 In none of 
these trials have we observed anything like the 
biochemical, radiological, and, importantly, 
symptomatic benefit reported with abiraterone 
acetate.
The results of our phase I study have been 
confirmed by a second phase I study in North 
America and four phase II studies run by our team 
and several North American investigators. These 
studies were recently presented at the American 
Society of Clinical Oncology annual meeting held 
in Chicago3-5 and will be published over the next 
year. The results remain preliminary and require 
confirmation in an ongoing 1180 patient phase 
III study, but they are very encouraging and 
